Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Bolomsky A, Muller J, Stangelberger K, Lejeune M, Duray E, Breid H, Vrancken L, Pfeiffer C, Hübl W, Willheim M, Weetall M, Branstrom A, Zojer N, Caers J, Ludwig H. Bolomsky A, et al. Among authors: weetall m. Br J Haematol. 2020 Sep;190(6):877-890. doi: 10.1111/bjh.16595. Epub 2020 Mar 30. Br J Haematol. 2020. PMID: 32232850 Free article.
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K. Nishida Y, et al. Among authors: weetall m. Blood Cancer J. 2017 Feb 17;7(2):e527. doi: 10.1038/bcj.2017.8. Blood Cancer J. 2017. PMID: 28211885 Free PMC article.
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, Du J, Sheedy J, Hedrick J, Risher N, Yeh S, Qi H, Arasu T, Hwang S, Lennox W, Kong R, Petruska J, Moon YC, Babiak J, Davis TW, Jacobson A, Almstead NG, Branstrom A, Colacino JM, Peltz SW. Cao L, et al. Among authors: weetall m. Mol Cancer Ther. 2019 Jan;18(1):3-16. doi: 10.1158/1535-7163.MCT-18-0863. Epub 2018 Oct 23. Mol Cancer Ther. 2019. PMID: 30352802 Free PMC article.
The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential.
Friesen WJ, Johnson B, Sierra J, Zhuo J, Vazirani P, Xue X, Tomizawa Y, Baiazitov R, Morrill C, Ren H, Babu S, Moon YC, Branstrom A, Mollin A, Hedrick J, Sheedy J, Elfring G, Weetall M, Colacino JM, Welch EM, Peltz SW. Friesen WJ, et al. Among authors: weetall m. PLoS One. 2018 Oct 25;13(10):e0206158. doi: 10.1371/journal.pone.0206158. eCollection 2018. PLoS One. 2018. PMID: 30359426 Free PMC article.
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Lennox W, Sheedy J, Weetall M, Yokote K, Iwama A, Sakaida E. Nagai Y, et al. Among authors: weetall m. Sci Rep. 2021 Jan 22;11(1):2074. doi: 10.1038/s41598-021-81577-x. Sci Rep. 2021. PMID: 33483574 Free PMC article.
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang J, Storti B, Castaño J, Panella R, Li J, Gustafson CE, Fox S, Levy RD, Meyerovitz CV, Tramontozzi PJ, Vermilya K, De Rienzo A, Crucitta S, Bassères DS, Weetall M, Branstrom A, Giorgetti A, Ciampi R, Del Re M, Danesi R, Bizzarri R, Yang H, Kocher O, Klein AM, Welner RS, Bueno R, Magli MC, Clohessy JG, Ali A, Tenen DG, Levantini E. Maroni G, et al. Among authors: weetall m. Commun Biol. 2021 Apr 14;4(1):370. doi: 10.1038/s42003-021-01897-6. Commun Biol. 2021. PMID: 33854168 Free PMC article.
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Jernigan F, Branstrom A, Baird JD, Cao L, Dali M, Furia B, Kim MJ, O'Keefe K, Kong R, Laskin OL, Colacino JM, Pykett M, Mollin A, Sheedy J, Dumble M, Moon YC, Sheridan R, Mühlethaler T, Spiegel RJ, Prota AE, Steinmetz MO, Weetall M. Jernigan F, et al. Among authors: weetall m. Mol Cancer Ther. 2021 Oct;20(10):1846-1857. doi: 10.1158/1535-7163.MCT-20-0774. Epub 2021 Jul 26. Mol Cancer Ther. 2021. PMID: 34315764 Free PMC article. Clinical Trial.
Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment.
Maroni G, Krishnan I, Alfieri R, Maymi VA, Pandell N, Csizmadia E, Zhang J, Weetall M, Branstrom A, Braccini G, Cabrera San Millán E, Storti B, Bizzarri R, Kocher O, Daniela Sanchez Bassères DS, Welner RS, Magli MC, Merelli I, Clohessy JG, Ali A, Tenen DG, Levantini E. Maroni G, et al. Among authors: weetall m. Cancer Res Commun. 2024 Mar 26;4(3):919-937. doi: 10.1158/2767-9764.CRC-23-0161. Cancer Res Commun. 2024. PMID: 38546390 Free PMC article.
BMI1 as a novel target for drug discovery in cancer.
Cao L, Bombard J, Cintron K, Sheedy J, Weetall ML, Davis TW. Cao L, et al. J Cell Biochem. 2011 Oct;112(10):2729-41. doi: 10.1002/jcb.23234. J Cell Biochem. 2011. PMID: 21678481 Review.
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Maeda A, Nishida Y, Weetall M, Cao L, Branstrom A, Ishizawa J, Nii T, Schober WD, Abe Y, Matsue K, Yoshimura M, Kimura S, Kojima K. Maeda A, et al. Among authors: weetall m. Oncotarget. 2018 Jun 19;9(47):28547-28560. doi: 10.18632/oncotarget.25558. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983879 Free PMC article.
78 results